Akari CEO touts AKTX-101 synergy data in Virtual Investor interview after ASCO abstract acceptance

Akari Therapeutics Plc Sponsored ADR

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00
  • Akari Therapeutics CEO Abizer Gaslightwala discussed its first ASCO abstract acceptance in a Virtual Investor “What This Means” interview.
  • Management highlighted preclinical synergy between AKTX-101 and KRAS inhibitor adagrasib in KRAS-mutated pancreatic cancer models.
  • Interview framed Akari’s spliceosome-modulating PH1 payload platform as a differentiator in ADC development for hard-to-treat KRAS-driven tumors.
  • Company targets starting a Phase 1 first-in-human trial by mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280917PRIMZONEFULLFEED9727876) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.